

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173759 A3

(51) International Patent Classification:

A61K 31/712 (2006.01) C12N 15/113 (2010.01)
A61K 31/7125 (2006.01) A61P 25/16 (2006.01)
C07H 21/04 (2006.01)

(21) International Application Number:

PCT/US2024/016097

(22) International Filing Date:

16 February 2024 (16.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/485,845 17 February 2023 (17.02.2023) US
63/587,718 03 October 2023 (03.10.2023) US

(71) Applicant: IONIS PHARMACEUTICALS, INC.

[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: ZHAO, Hien, Thuy; c/o Ionis Pharmaceuti-

cals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US).
FREIER, Susan, M.; c/o Ionis Pharmaceuticals, Inc., 2855
Gazelle Court, Carlsbad, CA 92010 (US). WAN, W., Brad;
c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carls-
bad, CA 92010 (US). THOMAS, Antony; c/o Ionis Phar-
maceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010
(US). MIGAWA, Michael, T.; c/o Ionis Pharmaceuti-
cals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US).
SETH, Punit, P.; 6773 Mallee St., Carlsbad, CA 92011
(US). FITZSIMMONS, Bethany; c/o Ionis Pharmaceuti-
cals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(74) Agent: HEMMENDINGER, Lisa, M. et al.; Banner &

Witcoff, Ltd., 1100 13th Street, N.W., Suite 1200, Washing-
ton, District of Columbia 20005-4051 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

24 October 2024 (24.10.2024)

(54) Title: COMPOUNDS AND METHODS FOR MODULATING ALPHA-SYNUCLEIN EXPRESSION

(57) Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use for reducing the amount or activity of SNCA mRNA in a cell or subject, and in certain instances reducing the amount of alpha-synuclein protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of a synucleinopathy. Such synucleinopathies include Parkinson's disease, dementia with Lewy bodies (DLB), diffuse Lewy body disease, Parkinson's disease dementia (PDD), pure autonomic failure, multiple system atrophy (MSA), neuronopathic Gaucher's disease, and Alzheimer's disease.



WO 2024/173759 A3